Latest filings (excl ownership)
6-K
Current report (foreign)
23 Apr 24
6-K
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
19 Apr 24
20-F
2023 FY
Annual report (foreign)
13 Mar 24
6-K
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 24
6-K
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
15 Feb 24
6-K
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
19 Jan 24
6-K
Current report (foreign)
5 Jan 24
6-K
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
8 Dec 23
6-K
Current report (foreign)
7 Nov 23
6-K
ProQR Therapeutics Provides Update on Ophthalmic Assets
27 Sep 23
6-K
Current report (foreign)
3 Aug 23
6-K
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
1 Aug 23
6-K
Current report (foreign)
17 May 23
6-K
Current report (foreign)
16 May 23
EFFECT
Notice of effectiveness
25 Apr 23
424B5
Prospectus supplement for primary offering
24 Apr 23
CORRESP
Correspondence with SEC
20 Apr 23
6-K
Current report (foreign)
18 Apr 23
UPLOAD
Letter from SEC
4 Apr 23
RW
Registration withdrawal request
29 Mar 23
F-3
Shelf registration (foreign)
29 Mar 23
20-F
2022 FY
Annual report (foreign)
29 Mar 23
6-K
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
29 Mar 23
6-K
Current report (foreign)
10 Mar 23
6-K
Current report (foreign)
23 Dec 22
6-K
Current report (foreign)
9 Nov 22
6-K
Current report (foreign)
21 Sep 22
6-K
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
11 Aug 22
6-K
Current report (foreign)
4 Aug 22
6-K
Current report (foreign)
30 Jun 22
6-K
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
1 Jun 22
6-K
Current report (foreign)
5 May 22
20-F
2021 FY
Annual report (foreign)
29 Apr 22
6-K
Current report (foreign)
13 Apr 22
6-K
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
13 Apr 22
424B5
Prospectus supplement for primary offering
10 Mar 22
EFFECT
Notice of effectiveness
10 Mar 22
CORRESP
Correspondence with SEC
7 Mar 22
UPLOAD
Letter from SEC
4 Mar 22
F-3
Shelf registration (foreign)
1 Mar 22
Latest ownership filings
SC 13G/A
VAN HERK INVESTMENTS B.V.
14 Feb 24
SC 13G/A
VAN HERK INVESTMENTS B.V.
9 Feb 24
SC 13G
VAN HERK INVESTMENTS B.V.
14 Sep 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Stichting Aescap Life Sciences
9 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
SC 13G/A
ELI LILLY & Co
23 Dec 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 May 22
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 22
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
10 Feb 22
SC 13G
FMR LLC
9 Feb 22
SC 13G/A
GOLDMAN SACHS GROUP INC
7 Feb 22
SC 13G/A
Stichting Aescap Life Sciences
4 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 22
SC 13G
ELI LILLY & Co
10 Sep 21
SC 13G/A
RTW INVESTMENTS, LP
6 Apr 21
SC 13G/A
GOLDMAN SACHS & CO. LLC
12 Feb 21
SC 13G/A
RTW INVESTMENTS, LP
12 Feb 21
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
11 Feb 21
SC 13G/A
JENNISON ASSOCIATES LLC
10 Feb 21
SC 13G/A
Stichting Aescap 2.0
9 Feb 21
SC 13G/A
PRUDENTIAL FINANCIAL INC
9 Feb 21
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
3 Feb 21
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
ProQR Therapeutics N.V.
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
11 Feb 20
SC 13G/A
Beneficial ownership report (amended)
7 Feb 20
SC 13G/A
Beneficial ownership report (amended)
3 Feb 20
SC 13G/A
ProQR Therapeutics N.V.
29 Jan 20
SC 13G/A
Beneficial ownership report (amended)
28 Jan 20
SC 13G/A
ProQR Therapeutics N.V.
27 Jan 20
SC 13G
ProQR Therapeutics N.V.
8 Nov 19
SC 13G
ProQR Therapeutics N.V.
28 Aug 19
SC 13G
ProQR Therapeutics N.V.
22 Feb 19
SC 13G
ProQR Therapeutics N.V.
15 Feb 19
SC 13G/A
ProQR Therapeutics N.V.
14 Feb 19
SC 13G/A
ProQR Therapeutics N.V.
14 Feb 19
SC 13G/A
ProQR Therapeutics N.V.
13 Feb 19